246 related articles for article (PubMed ID: 22912742)
1. Cardiac-specific over-expression of epidermal growth factor receptor 2 (ErbB2) induces pro-survival pathways and hypertrophic cardiomyopathy in mice.
Sysa-Shah P; Xu Y; Guo X; Belmonte F; Kang B; Bedja D; Pin S; Tsuchiya N; Gabrielson K
PLoS One; 2012; 7(8):e42805. PubMed ID: 22912742
[TBL] [Abstract][Full Text] [Related]
2. Examining the protective role of ErbB2 modulation in human-induced pluripotent stem cell-derived cardiomyocytes.
Eldridge S; Guo L; Mussio J; Furniss M; Hamre J; Davis M
Toxicol Sci; 2014 Oct; 141(2):547-59. PubMed ID: 25055963
[TBL] [Abstract][Full Text] [Related]
3. Echocardiographic Characterization of a Murine Model of Hypertrophic Obstructive Cardiomyopathy Induced by Cardiac-specific Overexpression of Epidermal Growth Factor Receptor 2.
Sørensen LL; Bedja D; Sysa-Shah P; Liu H; Maxwell A; Yi X; Pozios I; Olsen NT; Abraham TP; Abraham R; Gabrielson K
Comp Med; 2016; 66(4):268-77. PubMed ID: 27538857
[TBL] [Abstract][Full Text] [Related]
4. Bidirectional cross-regulation between ErbB2 and β-adrenergic signalling pathways.
Sysa-Shah P; Tocchetti CG; Gupta M; Rainer PP; Shen X; Kang BH; Belmonte F; Li J; Xu Y; Guo X; Bedja D; Gao WD; Paolocci N; Rath R; Sawyer DB; Naga Prasad SV; Gabrielson K
Cardiovasc Res; 2016 Mar; 109(3):358-73. PubMed ID: 26692570
[TBL] [Abstract][Full Text] [Related]
5. ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor.
Juliachs M; Castillo-Ávila W; Vidal A; Piulats JM; Garcia Del Muro X; Condom E; Hernández-Losa J; Teixidó C; Pandiella A; Graupera M; Casanovas O; Germà JR; Villanueva A; Viñals F
Int J Cancer; 2013 Jul; 133(1):235-46. PubMed ID: 23292912
[TBL] [Abstract][Full Text] [Related]
6. Essential roles of Her2/erbB2 in cardiac development and function.
Negro A; Brar BK; Lee KF
Recent Prog Horm Res; 2004; 59():1-12. PubMed ID: 14749494
[TBL] [Abstract][Full Text] [Related]
7. Gi alpha 1-mediated cardiac electrophysiological remodeling and arrhythmia in hypertrophic cardiomyopathy.
Ruan H; Mitchell S; Vainoriene M; Lou Q; Xie LH; Ren S; Goldhaber JI; Wang Y
Circulation; 2007 Aug; 116(6):596-605. PubMed ID: 17646583
[TBL] [Abstract][Full Text] [Related]
8. Induced Pluripotent Stem Cell-Derived Cardiomyocytes from a Patient with MYL2-R58Q-Mediated Apical Hypertrophic Cardiomyopathy Show Hypertrophy, Myofibrillar Disarray, and Calcium Perturbations.
Zhou W; Bos JM; Ye D; Tester DJ; Hrstka S; Maleszewski JJ; Ommen SR; Nishimura RA; Schaff HV; Kim CS; Ackerman MJ
J Cardiovasc Transl Res; 2019 Oct; 12(5):394-403. PubMed ID: 30796699
[TBL] [Abstract][Full Text] [Related]
9. Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy.
Tsybouleva N; Zhang L; Chen S; Patel R; Lutucuta S; Nemoto S; DeFreitas G; Entman M; Carabello BA; Roberts R; Marian AJ
Circulation; 2004 Mar; 109(10):1284-91. PubMed ID: 14993121
[TBL] [Abstract][Full Text] [Related]
10. Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice.
Condorelli G; Drusco A; Stassi G; Bellacosa A; Roncarati R; Iaccarino G; Russo MA; Gu Y; Dalton N; Chung C; Latronico MV; Napoli C; Sadoshima J; Croce CM; Ross J
Proc Natl Acad Sci U S A; 2002 Sep; 99(19):12333-8. PubMed ID: 12237475
[TBL] [Abstract][Full Text] [Related]
11. Mesenchymal Stem Cells and Cardiomyocytes Interplay to Prevent Myocardial Hypertrophy.
Cai B; Tan X; Zhang Y; Li X; Wang X; Zhu J; Wang Y; Yang F; Wang B; Liu Y; Xu C; Pan Z; Wang N; Yang B; Lu Y
Stem Cells Transl Med; 2015 Dec; 4(12):1425-35. PubMed ID: 26586774
[TBL] [Abstract][Full Text] [Related]
12. The PTPN11 loss-of-function mutation Q510E-Shp2 causes hypertrophic cardiomyopathy by dysregulating mTOR signaling.
Schramm C; Fine DM; Edwards MA; Reeb AN; Krenz M
Am J Physiol Heart Circ Physiol; 2012 Jan; 302(1):H231-43. PubMed ID: 22058153
[TBL] [Abstract][Full Text] [Related]
13. Zinc pyrithione inhibits caspase-3 activity, promotes ErbB1-ErbB2 heterodimerization and suppresses ErbB2 downregulation in cardiomyocytes subjected to ischemia/reperfusion.
Bodiga VL; Thokala S; Vemuri PK; Bodiga S
J Inorg Biochem; 2015 Dec; 153():49-59. PubMed ID: 26436560
[TBL] [Abstract][Full Text] [Related]
14. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
[TBL] [Abstract][Full Text] [Related]
15. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer.
Hickinson DM; Klinowska T; Speake G; Vincent J; Trigwell C; Anderton J; Beck S; Marshall G; Davenport S; Callis R; Mills E; Grosios K; Smith P; Barlaam B; Wilkinson RW; Ogilvie D
Clin Cancer Res; 2010 Feb; 16(4):1159-69. PubMed ID: 20145185
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2.
Karakashev SV; Reginato MJ
Oncotarget; 2015 Feb; 6(4):1967-80. PubMed ID: 25596742
[TBL] [Abstract][Full Text] [Related]
17. Radiation- and anthracycline-induced cardiac toxicity and the influence of ErbB2 blocking agents.
Seemann I; te Poele JA; Song JY; Hoving S; Russell NS; Stewart FA
Breast Cancer Res Treat; 2013 Oct; 141(3):385-95. PubMed ID: 24091769
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of cardiotoxicity associated with ErbB2 inhibitors.
Fedele C; Riccio G; Malara AE; D'Alessio G; De Lorenzo C
Breast Cancer Res Treat; 2012 Jul; 134(2):595-602. PubMed ID: 22674190
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy.
Grazette LP; Boecker W; Matsui T; Semigran M; Force TL; Hajjar RJ; Rosenzweig A
J Am Coll Cardiol; 2004 Dec; 44(11):2231-8. PubMed ID: 15582322
[TBL] [Abstract][Full Text] [Related]
20. Decreased contractility due to energy deprivation in a transgenic rat model of hypertrophic cardiomyopathy.
Luedde M; Flögel U; Knorr M; Grundt C; Hippe HJ; Brors B; Frank D; Haselmann U; Antony C; Voelkers M; Schrader J; Most P; Lemmer B; Katus HA; Frey N
J Mol Med (Berl); 2009 Apr; 87(4):411-22. PubMed ID: 19189074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
